Abbott

164 articles with Abbott

• U.S. FDA Clears Abbott's FreeStyle Libre® 2 and FreeStyle Libre® 3 Sensors for Integration with Automated Insulin Delivery Systems

  3/6/2023

  Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system sensors for integration with automated insulin delivery (AID) systems.

• FDA Approves Abbott's Spinal Cord Stimulation for People Living with Painful Diabetic Peripheral Neuropathy

  1/26/2023

  Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved its Proclaim™ XR spinal cord stimulation (SCS) system to treat painful diabetic peripheral neuropathy (DPN), a debilitating complication of diabetes.

• Abbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook

  1/25/2023

  Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2022.

• Abbott Hosts Conference Call for Fourth-Quarter Earnings - January 4, 2023

  1/4/2023

  Abbott (NYSE: ABT) will announce its fourth-quarter 2022 financial results on Wednesday, Jan. 25, 2023, before the market opens. 

• Abbott to Present at J.P. Morgan Healthcare Conference-December 20, 2022

  12/20/2022

  Abbott (NYSE: ABT) will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2023.

• Abbott Reports Third-Quarter 2022 Results and Raises Full-Year EPS Guidance

  10/19/2022

  Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2022.

• Abbott Hosts Conference Call for Third-Quarter 2022 Earnings

  9/28/2022

  Abbott will announce its third-quarter 2022 financial results on Wednesday, Oct. 19, 2022, before the market opens.

• Abbott Reports Second-Quarter 2022 Results and Raises Full-Year EPS Guidance

  7/20/2022

  Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2022.

• Abbott Hosts Conference Call for Second-Quarter Earnings - June 29, 2022

  6/29/2022

  Abbott will announce its second-quarter 2022 financial results on Wednesday, July 20, 2022, before the market opens.

• Late-Breaking Data Demonstrate Abbott's FreeStyle Libre® 3 System is Most Accurate 14-Day Continuous Glucose Monitor

  6/5/2022

  Abbott announced late-breaking clinical data that demonstrate the FreeStyle Libre® 3 system has an overall mean absolute relative difference of 7.9%,1 making it the first and only 14-day continuous glucose monitoring system to achieve a sub-8% overall MARD.

• Abbott Enters into Consent Decree with U.S. Food and Drug Administration for its Sturgis, Mich., Plant; Agreement Creates Pathway to Reopen Facility

  5/16/2022

  Abbott has agreed to enter into a consent decree with the U.S. Food and Drug Administration related to its Sturgis, Mich., infant formula plant.

• Abbott Obtains FDA Clearance for First Test that Simultaneously Detects Four Common Sexually Transmitted Infections (STIs) as Cases are on the Rise

  5/4/2022

  Abbott announced it has received FDA clearance for its Alinity™ m STI Assay.

• Abbott Reports First-Quarter 2022 Results

  4/20/2022

  Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2022.

• Abbott Receives FDA Approval for Aveir™ VR Leadless Pacemaker System to Treat Patients with Slow Heart Rhythms

  4/4/2022

  Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Aveir™ single-chamber (VR) leadless pacemaker for the treatment of patients in the U.S. with slow heart rhythms.

• Abbott's CardioMEMS™ HF System Receives FDA Approval to Support Patients Battling Earlier-Stage Heart Failure

  2/21/2022

  Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for the company's CardioMEMS™ HF System to support the care of more people living with heart failure.

• Abbott Declares 393rd Consecutive Quarterly Dividend

  2/18/2022

  The board of directors of Abbott declared a quarterly common dividend of 47 cents per share.

• Abbott Announces World's First Implant of Dual-Chamber Leadless Pacemaker in Pivotal Trial

  2/7/2022

  Abbott's investigational Aveir™ DR dual-chamber pacemaker is designed to provide synchronous, beat-by-beat pacing of the right atrium and right ventricle of the heart.

• Abbott Reports Strong Fourth-Quarter 2021 Results; Issues 2022 Forecast

  1/26/2022

  Abbott (NYSE: ABT) today announced financial results for the fourth quarter and full year ended Dec. 31, 2021, and issued its financial outlook for 2022.

• Abbott Hosts Conference Call for Fourth-Quarter 2021 Earnings

  1/4/2022

  Abbott will announce its fourth-quarter 2021 financial results on Wednesday, Jan. 26, 2022, before the market opens.

• Abbott to Present at J.P. Morgan Healthcare Conference - Dec 21, 2021

  12/21/2021

  Abbott will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 11, 2022. Robert B. Ford, chairman and chief executive officer, will present at 8 a.m. Central time.